Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL

Summary

This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD08 administered by intramuscular (IM) injection followed by electroporation (EP) in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 \[CIN2\] or grade 3 \[CIN3\]) associated with human papillomavirus (HPV) 16 and/or HPV18.

Timeline

Start

2025-11-11

Primary completion

2027-05-30

Completion

2027-08-30

Drugs

Indications